Back to News
Market Impact: 0.4

Kodak (KODK) Q4 2025 Earnings Call Transcript

KODKNFLXNVDA
Corporate EarningsCompany FundamentalsM&A & RestructuringManagement & GovernanceProduct LaunchesCredit & Bond MarketsCapital Returns (Dividends / Buybacks)

Kodak completed a $1.023B pension reversion (net $870M after a $153M excise tax), boosting unrestricted cash to $337M and enabling ~$312M of term‑loan paydown (term loan reduced by $303M to $200M). Q4 revenue was $290M (+9% YoY) with gross profit $67M (+31%, margin 23%) and operational EBITDA $22M (+144% YoY), though GAAP Q4 net loss was $108M mainly due to the excise tax; adjusted Q4 net loss was $12M. Management amended Series B preferred (extended to June 2029, dividend rate to 6%, conversion price $10) and highlights strengthened liquidity, lower interest expense from deleveraging, and continued revenue growth across AM&C (Q4 +25%) and Print (PROSPER 520 rollout, AI service investments).

Analysis

Kodak's corporate housekeeping (de-risking the pension and swapping shorter-term, higher-cost claims for a stretched obligation) materially changes the mapping from EBITDA to free cash flow; the immediate effect is mechanical—less volatility from pension accounting and a deterministic interest-cost trajectory—but the non-obvious lever is multiple expansion. With a now-transparent path to lower recurring cash interest and a clearer CAPEX profile for the print/AM&C businesses, the market should re-rate at a higher EV/EBITDA if management can convert incremental operational EBITDA into sustained FCF over the next 4–8 quarters. Second-order winners are service and consumables suppliers tied to plates, film and pharma packaging. If Kodak sustains higher run-rates in its print systems and still-film SKUs, a handful of upstream aluminum and coating suppliers will see stickier, higher-margin orders; conversely, commodity-sensitive competitors with higher leverage are at risk if pricing normalizes. Brand-licensing growth in Asia is low-capex and scalable — it acts like an annuity on gross margin without adding industrial cyclicality, amplifying downside protection for the equity if industrial demand softens. Key risks live in execution cadence and capital markets mechanics. Pharma-class certifications and industrial-scale ramp of PROSPER-like platforms are multi-quarter programs where a single regulatory miss or a production setback can wipe out near-term optimism; similarly, the preferred-equity amendment trades time for cash but raises a steady dividend drain and creates a conversion overhang that can cap upside until later expiration. For positioning, think in time buckets: 0–3 months where governance/extension optics dominate; 3–12 months where operational EBITDA should be validated; and 12–36 months where certification and structural growth drive re-rating.